Regulatory News : BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), Société d’innovation dédiée aux produits orphelins en cancérologie et aux produits de spécialité, annonce...
First semester 2013 Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and Validive® (phase II...
Regulatory News : BioAlliance Pharma (Paris:BIO) : Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général...
Regulatory News : BioAlliance Pharma (Paris:BIO) : Conformément à l’article L. 233-8 II du Code de commerce et à l’article 223-16 du Règlement général de l’Autorité des Marchés...
Montant brut levé : 8,7 millions d’euros ; Opération sursouscrite à hauteur de 155 % ; Exercice de la clause d’extension.
Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company dedicated to the development of orphan oncology products and supportive care products, announces it was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.600001 | -1.41509669811 | 42.4 | 42.4 | 40.4 | 44 | 40.45454545 | DE |
4 | 0.799999 | 1.95121707317 | 41 | 42.4 | 40.4 | 44 | 40.65971831 | DE |
12 | 0.599999 | 1.45630825243 | 41.2 | 42.4 | 40.4 | 51 | 41.03811678 | DE |
26 | 0.199999 | 0.480766826923 | 41.6 | 42.4 | 40.4 | 51 | 41.26140637 | DE |
52 | -0.800001 | -1.87793661972 | 42.6 | 42.6 | 40 | 57 | 41.44881451 | DE |
156 | -0.800001 | -1.87793661972 | 42.6 | 44.6 | 39.4 | 373 | 42.59904159 | DE |
260 | 22.549999 | 117.142851948 | 19.25 | 44.6 | 17.2 | 1357 | 31.83304993 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.